Sponsors (12)
The bill increases drug-label transparency and speeds recalls and import processing—benefiting patients, hospitals, and some importers—at the cost of added compliance and administrative burdens, potential temporary supply disruptions, and new legal/confidentiality tensions between FDA labeling and customs/origin rules.
Patients (including those with chronic conditions) and hospitals can verify drug origin and traceability because finished-drug labels (or linked portals) must identify original API manufacturers, finished-product manufacturers, and packers/distributors.
Hospitals and pharmacies gain better supply‑chain visibility via required unique facility identifiers and electronically available manufacturer information, improving inventory management and procurement decisions.
Patients and health systems benefit from faster, more accurate recalls and safety investigations because labels include the original manufacturer and unique facility identifiers.
Manufacturers, packers, distributors, and importers will face increased compliance costs, relabeling and portal‑maintenance burdens, and legal uncertainty where FDA labeling and customs expectations conflict.
Hospitals, pharmacies, and patients risk temporary shortages or distribution disruptions as older inventory is relabeled or removed to meet new labeling requirements.
Consumers could receive less transparent country‑of‑origin information on some drug articles if FDA labels do not include the same customs-origin details previously provided under traditional marking rules.
Based on analysis of 3 sections of legislative text.
Requires drug and API labels (or linked electronic portals) to show manufacturer/packer/distributor name, place of business, and unique facility ID and identifies original API manufacturers; creates a customs marking exception for compliant imports.
Official title: Amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information.
Introduced February 5, 2026 by Richard Lynn Scott · Last progress February 5, 2026
Requires more detailed, traceable labeling for drugs and active pharmaceutical ingredients (APIs). Drug labels (or linked electronic portals) must identify the manufacturer/packer/distributor by name, place of business, and a unique facility identifier, and finished products must identify the original manufacturer(s) of each API and the original finished-product manufacturer; HHS will issue implementation rules with at least a one-year lead time. Also creates a customs marking exception so imported finished drug products that meet the new FDA labeling rule do not need separate country-of-origin markings under the Tariff Act, effectively allowing FDA-compliant drug labeling to serve as the operative import marking for those products.